

David Rosmarin, MD

Vice Chair for Research and Education

Tufts Medical Center

Boston, Massachusetts, USA

Dr. Rosmarin is a clinical investigator and Vice-Chair for Research and Education at Tufts Medical Center, focusing on clinical trials for inflammatory disorders of the skin. Dr. Rosmarin attended medical school at New York University and completed his dermatology residency at Boston University-Tufts combined training program and his fellowship at Brigham and Women's Hospital. Dr. Rosmarin joined Tufts Medical Center in 2013 focusing as a clinical trial investigator. In 2016 Dr. Rosmarin became the Director of the Clinical Trials Unit in the Department of Dermatology at Tufts Medical Center.

Notably, Dr. Rosmarin has served as the principal investigator for multiple investigator-initiated trials for a topical JAK inhibitor for vitiligo, the use of an oral JAK inhibitor for discoid lupus, and for an anti-IL17 antibody to treat hidradenitis suppurativa. These studies have resulted in Dr. Rosmarin becoming the PI for a multicentered trial evaluating topical ruxolitinib in vitiligo which will likely lead to the first ever FDA indication for repigmenting vitiligo. Dr. Rosmarin is the first to use dupilumab for bullous pemphigoid which is now in a phase 3 program for an indication. Clinically, Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult to manage inflammatory diseases such as atopic dermatitis. Dr. Rosmarin educates medical students, residents, and research fellows. He has led the medical student clerkship since 2014, innovating in the use of a simulation center for teaching. Dr. Rosmarin served as Residency Program Director from 2016 to 2020 during which time he expanded the Tufts Medical Residency Program from nine positions to twelve residents, and he mentors faculty in education and research.